ZA200501869B - Liquid stable composition of oxazaphosphorine with mesna - Google Patents

Liquid stable composition of oxazaphosphorine with mesna

Info

Publication number
ZA200501869B
ZA200501869B ZA200501869A ZA200501869A ZA200501869B ZA 200501869 B ZA200501869 B ZA 200501869B ZA 200501869 A ZA200501869 A ZA 200501869A ZA 200501869 A ZA200501869 A ZA 200501869A ZA 200501869 B ZA200501869 B ZA 200501869B
Authority
ZA
South Africa
Prior art keywords
oxazaphosphorine
mesna
cyclodextrin
stable composition
liquid stable
Prior art date
Application number
ZA200501869A
Other languages
English (en)
Inventor
Daftary Gautam Vinod
Pai Srikanth Annappa
Rivankar Sangeeta Hanurmesh
Praveen Kumar Subbappa
Original Assignee
Bharat Serums & Vaccines Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bharat Serums & Vaccines Ltd filed Critical Bharat Serums & Vaccines Ltd
Publication of ZA200501869B publication Critical patent/ZA200501869B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Detergent Compositions (AREA)
ZA200501869A 2002-09-05 2005-03-04 Liquid stable composition of oxazaphosphorine with mesna ZA200501869B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN809MU2002 2002-09-05

Publications (1)

Publication Number Publication Date
ZA200501869B true ZA200501869B (en) 2007-11-28

Family

ID=31503923

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200501869A ZA200501869B (en) 2002-09-05 2005-03-04 Liquid stable composition of oxazaphosphorine with mesna

Country Status (16)

Country Link
US (1) US20050272698A1 (xx)
EP (1) EP1396268B1 (xx)
JP (1) JP2006508917A (xx)
KR (1) KR101037313B1 (xx)
CN (1) CN1694713A (xx)
AT (1) ATE328598T1 (xx)
AU (1) AU2003276689B2 (xx)
BR (1) BR0314068A (xx)
CA (1) CA2497898C (xx)
DE (1) DE60305813T2 (xx)
EA (1) EA008776B1 (xx)
ES (1) ES2266734T3 (xx)
MX (1) MXPA05002453A (xx)
NZ (1) NZ538584A (xx)
WO (1) WO2004022699A2 (xx)
ZA (1) ZA200501869B (xx)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004050012A2 (en) * 2002-12-02 2004-06-17 Bharat Serums And Vaccines Ltd Ifosfamide compositions for parenteral administration and a process for their preparation
DE10346134A1 (de) * 2003-10-01 2005-04-21 Baxter Healthcare Sa Neue Verwendung, pharmazeutische Zubereitungen sowie Verfahren zu deren Herstellung
DK1667655T3 (da) * 2003-10-01 2011-10-24 Baxter Int Ny anvendelse, farmaceutiske præparater og en fremgangsmåde til deres fremstilling
KR20070058608A (ko) * 2004-09-13 2007-06-08 바라트 쎄럼스 앤드 백신스 리미티드 항미생물 방부 효능을 갖는 정맥 내 투여를 위한 안정한에멀젼 조성물
EP2345412A1 (en) * 2005-12-02 2011-07-20 The Johns Hopkins University Use of high-dose oxazaphosphorine drugs for treating immune disorders
WO2008034076A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Cyclophosphamide in combination with immune therapeutics
WO2008034074A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Cyclosphosphamide in combination with anti-idiotypic vaccines
WO2008034071A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Method of identifying patients suitable for high-dose cyclophosphamide treatment
WO2009067699A2 (en) * 2007-11-21 2009-05-28 Accentia Biopharmaceuticals, Inc. Methods for providing a system of care for an oxazaphosphorine drug regimen
US9026372B2 (en) * 2007-11-21 2015-05-05 Accentia Biopharmaceuticals, Inc. Methods for providing a system of care for a high-dose oxazaphosphorine drug regimen
US10849916B2 (en) 2014-07-11 2020-12-01 Dr. Reddys Laboratories Limited Stable liquid formulations of cyclophosphamide and its impurities
WO2016005962A2 (en) 2014-07-11 2016-01-14 Dr. Reddy’S Laboratories Limited Stable liquid formulations of cyclophosphamide and processes

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0002495B1 (de) * 1977-12-14 1984-02-15 Asta-Werke Aktiengesellschaft Chemische Fabrik Erzeugnisse zur Anwendung in der cytostatischen Therapie
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US6407079B1 (en) * 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
ATE66609T1 (de) * 1986-07-11 1991-09-15 Asta Pharma Ag Loesungen von oxazaphosphorinen mit verbesserter stabilitaet und verfahren zu deren herstellung.
NO873860L (no) * 1986-10-31 1988-05-02 Asta Pharma Ag Ifosfamid-lyofilisat og fremgangsmaate til deres fremstilling.
US4879286A (en) * 1987-01-28 1989-11-07 Lyphomed, Inc. Cyclophosphamide
ATE65402T1 (de) * 1988-03-19 1991-08-15 Asta Pharma Ag Ifosfamid-mesna-lyophilisat und verfahren zu dessen herstellung.
IE62095B1 (en) * 1988-03-29 1994-12-14 Univ Florida Pharmaceutical formulations for parenteral use
EP0491812A4 (en) * 1989-09-14 1992-11-04 Australian Commercial Research & Development Limited Drug delivery compositions
US5227373A (en) * 1991-10-23 1993-07-13 Bristol-Myers Squibb Co. Lyophilized ifosfamide compositions
US5602112A (en) * 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
SI9300470A (en) * 1993-09-10 1995-04-30 Lek Tovarna Farmacevtskih Inclusion complexes of optically active and racemic ibuproxan with cyclodextrin derivates,process for their preparation,pharmaceutical preparations comprising the same and their use
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
PL178713B1 (pl) * 1995-03-31 2000-06-30 Centrum Badan Molekularnych I Makromolekularnych Pan Środek farmaceutyczny o działaniu przeciwnowotworowym
DE19733305A1 (de) * 1997-08-01 1999-02-04 Asta Medica Ag Pharmazeutische Zusammensetzung enthaltend Ifosfamid und Carnitin
ITMI20011338A1 (it) 2001-06-26 2002-12-26 Farmatron Ltd Composizioni farmaceutiche orali a rilascio immediato del principio attivo

Also Published As

Publication number Publication date
CA2497898A1 (en) 2004-03-18
WO2004022699A2 (en) 2004-03-18
DE60305813T2 (de) 2007-06-28
ATE328598T1 (de) 2006-06-15
EP1396268B1 (en) 2006-06-07
KR101037313B1 (ko) 2011-05-26
BR0314068A (pt) 2005-07-05
ES2266734T3 (es) 2007-03-01
KR20050057229A (ko) 2005-06-16
CA2497898C (en) 2012-02-07
AU2003276689B2 (en) 2009-04-09
JP2006508917A (ja) 2006-03-16
NZ538584A (en) 2007-05-31
MXPA05002453A (es) 2005-05-27
DE60305813D1 (de) 2006-07-20
AU2003276689A1 (en) 2004-03-29
EA008776B1 (ru) 2007-08-31
EP1396268A1 (en) 2004-03-10
EA200500315A1 (ru) 2005-08-25
WO2004022699A3 (en) 2005-03-24
US20050272698A1 (en) 2005-12-08
CN1694713A (zh) 2005-11-09

Similar Documents

Publication Publication Date Title
ZA200501869B (en) Liquid stable composition of oxazaphosphorine with mesna
BR0116345A (pt) Composiçõs de contra-ação ao mau cheiro
TR200002366T2 (tr) Herbisit aktif 3-hidroksi-4-aril-5-oksopirazolin türevleri.
DE602006020883D1 (de) Haftklebemittelzusammensetzung auf acrylatbasis
MY141869A (en) Mouth rinse compositions
ATE504286T1 (de) Antitranspirant- oder deodorantzusammensetzungen
ATE408598T1 (de) Bicyclische verbindung
MY158003A (en) Antibacterial 3',5-disubtituted 2,4'-dihydroproxybiphenyl compounds, derivatives and related methods
EP1358883B8 (en) Re-epithelializing pharmaceutical compositions containing xanthan gum
TW200604732A (en) A chemically amplified positive resist composition
BRPI0415034A (pt) derivados de aminopiridina como inibidores de não-sintase induzìveis
DE69940551D1 (de) Mercaptane und disulfide
TW200504459A (en) A sulfonate and a resist composition
DE502005008953D1 (de) Liponsäure-konzentrat
EP1580320A3 (en) Compositions for porous materials
AR043037A1 (es) Benzo [1,2,5] tiadiazoles y su uso farmaceutico
MX2007003174A (es) Sales de disulfuro medicinales.
WO2005011565A3 (fr) Vernis a ongles a action antimycosique
DE502005008686D1 (en) Ats
BR0318037A (pt) Composição
AR048435A1 (es) Composicion estable liquida de oxazafosforina con mesna
BR0316968A (pt) Composições estáveis, claras, aquosas de ifosfamida para administração parenteral que apresentam pouca toxicidade; processo para a preparação de composições de ifosfamida; e composições de ifosfamida e um processo para a preparação das mesmas
CO5630012A2 (es) Mezclas fungicidas basadas en un derivado de triazolopirimidina
CO5670322A2 (es) Mezclas fungicidas
DE602004002781D1 (de) Wasserfreie lösung eines natriumsalzes von hedta